Maze Therapeutics (MAZE) Liabilities and Shareholders Equity (2024 - 2026)

Maze Therapeutics (MAZE) has 3 years of Liabilities and Shareholders Equity data on file, last reported at $419.7 million in Q1 2026.

• For the quarter ending Q1 2026, Liabilities and Shareholders Equity rose 26.1% year-over-year to $419.7 million; the trailing twelve-month figure through Mar 2026 stood at $1.5 billion (up 169.0% YoY), and the FY2025 full-year result was $397.1 million, up 65.1% from the prior year.
• Liabilities and Shareholders Equity rose to $419.7 million in Q1 2026, from $397.1 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $422.1 million in Q3 2025 to a low of $240.5 million in Q4 2024.
• A 3-year average of $352.6 million and a median of $365.0 million in 2025 frame the typical range for Liabilities and Shareholders Equity.
• Across the five-year window, Liabilities and Shareholders Equity surged 65.1% in 2025 and advanced 26.1% in 2026, its largest moves.
• Tracing MAZE's Liabilities and Shareholders Equity over 3 years: stood at $240.5 million in 2024, then surged by 65.1% to $397.1 million in 2025, then increased by 5.69% to $419.7 million in 2026.
• Business Quant data shows MAZE's Liabilities and Shareholders Equity at $419.7 million in Q1 2026, $397.1 million in Q4 2025, and $422.1 million in Q3 2025.